Workbook sheet
Paying for a GLP-1 without insurance
Cash pay means you are buying the drug without the plan’s contribution. It does not mean every cash price is the same, and it does not mean a compounded vial is the cash version of an approved pen. This sheet uses manufacturer pages checked on November 18, 2026. Prices move. Before you pay, open the page again or use Cheapest GLP-1 Without Insurance, which exists to keep a price check current. This workbook will not pretend a November figure is a quote. The tirzepatide monograph is the dose context for Zepbound. A 2.5 mg price is a starting-dose price. A 15 mg price is a different month of treatment.
Two prices, two meanings
List price is the manufacturer’s posted price before rebates and offers. NovoCare’s explainer states that Wegovy has a list price of $1,349.02 per package, and that most people do not pay list price if insurance covers the drug. If insurance does not cover it and you do not use a self-pay offer, a pharmacy can charge an amount anchored to that list price, plus its own terms. Ask for the cash price before the claim is run, and ask whether a manufacturer offer would change it.
Self-pay price is the offer price for people using the manufacturer’s stated path. It can be much lower than list price and still be real money every 28 days. It can also be dose-specific, time-limited, or dependent on refilling inside a window.
Wegovy self-pay as published
From NovoCare’s Wegovy patient page, savings-offer page, and price-guide PDF:
| Product | Price published for a 28-day supply | Condition stated on the page |
|---|---|---|
| Pen, 0.25 mg or 0.5 mg, first two fills for a new patient | $199 | Offer described through December 31, 2026, then the standard price |
| Pen, 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, or 2.4 mg | $349 | Standard self-pay. One month is one box of four pens |
| HD pen, 7.2 mg | $399 | Standard self-pay for that strength |
| Tablet, 1.5 mg | $149 | One bottle of 30 tablets |
| Tablet, 4 mg | $199 | One bottle of 30 tablets |
| Tablet, 9 mg or 25 mg | $299 | One bottle of 30 tablets |
The pages say eligibility and restrictions apply and that the program can be modified or canceled. They say you use NovoCare home delivery or the savings offer at a pharmacy to get these prices. A two-month or three-month pen fill at the standard $349 price was shown as $698 and $1,047 in the delivery terms reviewed. Do not assume a 90-day fill is discounted below three times the monthly price unless the current table says so.
The commercial-insurance “as little as $25” offer is not this table. It excludes government beneficiaries and caps savings at $100 a month. If you have no commercial coverage, you are in the self-pay column, not the $25 column.
Zepbound self-pay as published
From the LillyDirect Zepbound page the same day:
The 2.5 mg KwikPen self-pay price was listed as starting at $299 per month. A month is 28 days and one KwikPen. Lilly notes that 2.5 mg is a starting dose and is not a maintenance dose.
For 7.5 mg and above, the page listed a Journey Program price starting at $449 per month when you refill within 45 days. If you miss that window, the footnote listed $499 for 7.5 mg and $699 for 10 mg, 12.5 mg, and 15 mg. The 45 days are why a “$449” ad can become a $699 refill. Put the refill date on a calendar if you are using that offer.
Vials at 10 mg, 12.5 mg, and 15 mg were listed on the same starting-at-$449 basis with a timely refill. A month of vials is four vials. Needles and syringes are extra. The 5 mg cash price is on the live page as its own line. This sheet leaves that dollar amount to the page rather than repeating a figure we could not confirm cleanly in review.
The single-dose pen’s “as low as $25” line is an insurance price. Governmental beneficiaries are excluded. It is not the self-pay vial price. Lilly says the program is not insurance and that terms can end.
Over a year, the difference between a starting-dose month and a maintenance-dose month is the budget. Someone who only multiplies $299 by twelve is pricing a dose the label says not to stay on. Someone who multiplies $699 by twelve is pricing the high end of the published regular price, not the timely-refill price. Do the multiplication that matches the dose you expect to be on, then add the visit.
What cash price does not buy
It does not buy labs, a clinician, or treatment of a complication. It does not buy a second GLP-1 to combine with the first. Labels say not to do that. It does not buy permanent weight loss if you later stop. Withdrawal trials are summarized in a maintenance note. Budgeting only for three months, because that is what feels affordable, is a clinical plan as well as a financial one. Talk about duration before you start, not when the card declines.
It does not equal a compounded subscription. FDA has said compounded GLP-1 products are not approved and are not generics. A lower compounded price can be a real price for a different object, with different measurement risk. If you are comparing them, compare on purpose. Do not let an advertisement do it with the word “semaglutide” alone.
It does not include pen needles for every device. Lilly says KwikPen needles and vial syringes are separate purchases. Add them once so they do not surprise you monthly.
A way to compare without fooling yourself
Write four lines: drug and strength, 28-day drug price and the page you saw it on, visit or membership fee, and supplies. Add them. Then write whether the price survives the next dose increase and a late refill. The Wegovy pen’s standard self-pay price, as published, did not change from 0.25 mg to 2.4 mg. The Zepbound self-pay price, as published, did change with dose and with refill timing. Those are different shapes. A single “cheapest” winner that ignores the shape is an ad, not a comparison.
Shipping and memberships belong in the same arithmetic. A mail pharmacy that charges nothing for shipping is not free if the membership is $79 every month. A clinic that advertises the drug “at cost” still has a visit. Write those numbers on the same line as the pen. Then ask what the second month costs if you are a new Wegovy patient whose first two pen fills were priced at the introductory $199. The standard price published beside that offer was $349. The third fill is the one that tells you whether you can continue. Do the same for a Zepbound refill that slips past 45 days. The footnote prices are the honest second number, and they are the ones people forget when they screenshot only the starting dose.
Savings offers restates the exclusions. Prior authorization is the sheet to try before you conclude you must pay cash. Some plans pay after paperwork. Some never will. Knowing which one you have is worth a phone call before a year of cash prices.
Sources checked for this sheet
- https://www.novocare.com/mash/resources/explaining-list-price.html
- https://www.novocare.com/patient/medicines/wegovy.html
- https://www.novocare.com/patient/medicines/wegovy/savings-offer.html
- https://www.novocare.com/content/dam/novonordisk/novocare/redesign/pdf/Wegovy_Price_Guide.pdf
- https://www.lilly.com/lillydirect/zepbound
- https://cheapestglp1withoutinsurance.com/
- https://glp1meds.org/monographs/tirzepatide
- https://glp1journey.org/notes/maintenance